

January 6, 2025

To,
BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Scrip Code: 531015

Sub: Notice of Board Meeting

Ref: Intimation of Board Meeting pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

We wish to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Saturday, January 11, 2025 *inter alia*, **to consider and evaluate** the following:

1. Increase in the Authorized Share Capital of the Company and consequent amendments in Memorandum and Articles of Association of the Company, if any;
2. The proposal to raise funds, to accelerate business growth of the Company, by way of issue of one or more instruments including Equity Shares, Convertible or Non-Convertible Securities of any description or Warrants, through Preferential Issue, Private Placements, Rights Issue (including determination of the issue price) or any other methods or combination thereof as may be permitted under applicable laws and **subject to all necessary approvals**, and to appoint requisite intermediaries required for this purpose;

3. Fix the date of Convening of Extra-Ordinary General Meeting of the Shareholder's seeking members' approval wherever necessary for the above-said board decisions and other matters connected therewith and/or incidental thereto and to approve Draft Notice of EGM to the Shareholders
4. Regularization of Mr. Sadhanala Venkata Rao (DIN: 02906370), Additional Director, as Director and Managing Director of the Company.
5. The proposal for investment in a Pharma Company.

In addition to the items listed herein above, the Board may consider any other matter with the permission of the Chair.

Further, in continuation to the intimation dated December 31, 2024 with reference to the closure of Trading window for dealing in securities of the Company, we would like to inform you that pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and in compliance with the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the Securities of the Company will continue to remain closed with effect from Wednesday, January 01, 2025 till 48 hours after the declaration of financial results of the Company for the quarter ended December 31, 2024.

We request you to take the same in your records.

Thanking you,

Yours Faithfully

for **Venmax Drugs & Pharmaceuticals Limited**

Dasi Rakesh Reddy
Director
DIN: 07112785